IBM three-lens brief
Evidence-based stock research on IBM. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Outperforming SPY by 15.1pp over 30 days. · Debt-to-equity of 211% — balance-sheet-heavy.
- Outperforming SPY by 15.1pp over 30 days.
- Debt-to-equity of 211% — balance-sheet-heavy.
- Earnings scheduled 2026-07-22.
IBM closed at $294.72 (-0.20%) as of 2026-07-10. Market cap: $277.00B. P/E (trailing) 26.1. Price is above the 50-day MA and above the 200-day MA. Positives: outperforming SPY by 15.1pp over 30 days.. Concerns: debt-to-equity of 211% — balance-sheet-heavy.. Last quarter: Revenue $15.92B, net income $1.22B, free cash flow $13.08B. Watching for: 2026-07-22 earnings release (11 days out).
Why three lenses on IBM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine IBMacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/IBM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath IBM brief"></iframe>